A method for treating or ameliorating mucocutaneous or ocular toxicities or side effects resulting from molecular targeted therapy, including administering to a subject in need thereof a pharmaceutical composition which contains a therapeutically effective amount of a histone deacetylase (HDAC) inhibitor, wherein the mucocutaneous or ocular toxicities or side effects result from molecular targeted therapy.
